A fully automated two-step synthesis of an 18F-labelled tyrosine kinase inhibitor for EGFR kinase activity imaging in tumors

Applied Radiation and Isotopes

Volumn 67, Issue 11, 2009, Pages 1977-1984

  Kobus, D ^a   Giesen, Y ^a   Ullrich, R ^a   Backes, H ^a   Neumaier, B ^a  

^a MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

Author keywords

Click chemistry; Epidermal growth factor receptor; Fluorine 18; Molecular imaging

Indexed keywords

AUTOMATED SYNTHESIS; CLICK CHEMISTRY; DIPOLAR CYCLOADDITIONS; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTORS; FLUORINE-18; KINASE ACTIVITY; MOLECULAR IMAGING; MULTI-STEP; OVER-EXPRESSION; PET IMAGES; QUINAZOLINES; TUMOR XENOGRAFTS; TWO-STEP SYNTHESIS; TYROSINE KINASE; TYROSINE KINASE INHIBITOR;

ACETYLENE; AMINO ACIDS; BIOACTIVITY; CYCLOADDITION; FLUORINE; LABELS; ONCOLOGY; RADIOISOTOPES; SYNTHESIS (CHEMICAL); TUMORS;

PEPTIDES;

6 (4 N,N DIMETHYLAMINOCROTONYL)AMIDO 4 (3 CHLORO 4 FLUORO)PHENYLAMINO 7 [3 [4 (2 FLUOROETHYL) 2,3,4 TRIAZOL 1 YL]PROPOXY]QUINAZOLINE F 18; ALKYNE; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; FLUORINE 18; FLUOROETHYLAZIDE F 18; PROTEIN TYROSINE KINASE INHIBITOR; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOMATION; CONTROLLED STUDY; CYCLOADDITION; DRUG STRUCTURE; ENZYME ACTIVITY; IMAGING; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYNTHESIS; TUMOR; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; FLUORINE RADIOISOTOPES; HUMANS; ISOTOPE LABELING; METABOLIC CLEARANCE RATE; MICE; ORGAN SPECIFICITY; PROTEIN-TYROSINE KINASES; RADIOPHARMACEUTICALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE DISTRIBUTION;

EID: 69549123869     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apradiso.2009.07.018     Document Type: Article

References (15)

1. Abourbeh G., Dissoki S., Jacobson O., Litchi A., Daniel R.B., Laki D., Levitzki A., and Mishani E. Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors. Nucl. Med. Biol. 34 1 (2007) 55-70
2. Bild A.H., Potti A., and Nevins J.R. Linking oncogenic pathways with therapeutic opportunities. Nat. Rev. Cancer 6 (2006) 735-741
3. Considine, J.L., Daigneault, S., Chew, W., Iera, S., Duncan, S.M., Ren, J., 2004. A large-scale synthesis of 4-amino-2-butenoyl chlorides, useful as intermediates in preparation of [(dimethylaminocrotonyl)amido]quinoline derivatives. PCT Int. Appl. WO 2004066919 A2.
4. Demko Z.P., and Sharpless K.B. An intramolecular [2+3] cycloaddition route to fused 5-heterosubstituted tetrazoles. Org. Lett. 3 25 (2001) 4091-4094
5. Dissoki S., Aviv Y., Laky D., Abourbeh G., Levitzki A., and Mishani E. The effect of the [18F]-PEG group on tracer qualification of [4-(phenylamino)-quinazolin-6-yl]-amide moiety-An EGFR putative irreversible inhibitor. Appl. Radiat. Isot. 65 10 (2007) 1140-1151
6. 11C]-labeled PD153035 in rats without and with neuroblastoma implants. Life Sci. 65 2 (1999) 165-174
7. Fry D.W., Bridges A.J., Denny W.A., Doherty A., Greis K.D., Hicks J.L., Hook K.E., Keller P.R., Leopold W.R., Loo J.A., McNamara D.J., Nelson J.M., Sherwood V., Smaill J.B., Trumpp-Kallmeyer S., and Dobrusin E.M. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc. Natl. Acad. Sci. USA 95 20 (1998) 12022-12027
8. Fry D.W. Mechanism of action of erbB tyrosine kinase inhibitors. Exp. Cell Res. 284 1 (2003) 131-139
9. 18F]fluoroethylazide for positron emission tomography. Bioconj. Chem. 18 3 (2007) 989-993
10. 18F]-labeling of RGD peptides and microPET imaging of tumor integrin αvβ3 expression. Bioconj. Chem. 18 6 (2007) 1987-1994
11. Lu G., Lam S., and Burgess K. An iterative route to decorated ethylene glycol-based linkers. Chem. Commun. 15 (2006) 1652-1654
12. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J. Clin. Oncol. 20 Suppl. 18 (2002) S1-S13
13. Pal A., Glekas A., Doubrovin M., Balatoni J., Namavari M., Beresten T., Maxwell D., Soghomonyan S., Shavrin A., Ageyeva L., Finn R., Larson S.M., Bornmann W., and Gelovani J.G. Molecular imaging of EGFR kinase activity in tumors with 124I -labeled small molecular tracer and positron emission tomography. Mol. Imaging Biol. 8 5 (2006) 262-277
14. Rewcastle G.W., Palmer B.D., Bridges A.J., Showalter H.D.H., Sun L., Nelson J., McMichael A., Kraker A.J., Fry D.W., and Denny W.A. Tyrosine kinase inhibitors. 9. synthesis and evaluation of fused tricyclic quinazoline analogs as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J. Med. Chem. 39 4 (1996) 918-928
15. Toffoli G., De Mattia E., Cecchin E., Biason P., Masier S., and Corona G. Pharmacology of epidermal growth factor inhibitors. Int. J. Biol. Markers 22 1, Suppl. 4 (2007) S24-S39